Rain Oncology Management
Management criteria checks 1/4
Rain Oncology's CEO is Avanish Vellanki, appointed in Apr 2017, has a tenure of 6.75 years. total yearly compensation is $2.19M, comprised of 27% salary and 73% bonuses, including company stock and options. directly owns 7.01% of the company’s shares, worth $3.09M. The average tenure of the management team and the board of directors is 1.9 years and 5.5 years respectively.
Key information
Avanish Vellanki
Chief executive officer
US$2.2m
Total compensation
| CEO salary percentage | 27.0% |
| CEO tenure | 6.8yrs |
| CEO ownership | 7.0% |
| Management average tenure | 1.9yrs |
| Board average tenure | 5.5yrs |
Recent management updates
Recent updates
Is Rain Oncology (NASDAQ:RAIN) In A Good Position To Invest In Growth?
Feb 23
We Think Rain Therapeutics (NASDAQ:RAIN) Needs To Drive Business Growth Carefully
Nov 08Rain Therapeutics GAAP EPS of -$0.66 in-line
Aug 04Here's Why We're Watching Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Situation
Aug 03We're Not Very Worried About Rain Therapeutics' (NASDAQ:RAIN) Cash Burn Rate
Apr 17We Think Rain Therapeutics (NASDAQ:RAIN) Can Afford To Drive Business Growth
Dec 25We're Hopeful That Rain Therapeutics (NASDAQ:RAIN) Will Use Its Cash Wisely
Sep 21CEO Compensation Analysis
| Date | Total Compensation | Salary | Company Earnings |
|---|---|---|---|
| Sep 30 2023 | n/a | n/a | -US$72m |
| Jun 30 2023 | n/a | n/a | -US$83m |
| Mar 31 2023 | n/a | n/a | -US$79m |
| Dec 31 2022 | US$2m | US$590k | -US$76m |
| Sep 30 2022 | n/a | n/a | -US$71m |
| Jun 30 2022 | n/a | n/a | -US$71m |
| Mar 31 2022 | n/a | n/a | -US$62m |
| Dec 31 2021 | US$818k | US$497k | -US$51m |
| Sep 30 2021 | n/a | n/a | -US$39m |
| Jun 30 2021 | n/a | n/a | -US$31m |
| Mar 31 2021 | n/a | n/a | -US$25m |
| Dec 31 2020 | US$729k | US$394k | -US$21m |
Compensation vs Market: Avanish's total compensation ($USD2.19M) is above average for companies of similar size in the US market ($USD717.13K).
Compensation vs Earnings: Avanish's compensation has increased whilst the company is unprofitable.
CEO
Avanish Vellanki (48 yo)
6.8yrs
Tenure
US$2,190,271
Compensation
Mr. Avanish Vellanki, M.B.A., co-founded Rain Therapeutics Inc in April 2017 and has been its Chief Executive Officer and Chairman since inception. Prior to Rain, Mr. Vellanki served as Senior Vice Preside...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.8yrs | US$2.19m | 7.01% $ 3.1m | |
| Co-Founder | 6.8yrs | US$1.43m | 1.31% $ 577.0k | |
| Principal Financial & Accounting officer | less than a year | no data | 0.0085% $ 3.7k | |
| Director of Corporate Development & Operations | no data | no data | no data | |
| General Counsel & Chief Compliance Officer | less than a year | no data | no data | |
| Vice President of People & Culture | no data | no data | no data | |
| Senior VP & Head of Research | no data | no data | no data | |
| MD & VP of Clinical Development | 1.9yrs | no data | no data |
1.9yrs
Average Tenure
49.5yo
Average Age
Experienced Management: RAIN's management team is not considered experienced ( 1.9 years average tenure), which suggests a new team.
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Co-Founder | 6.8yrs | US$2.19m | 7.01% $ 3.1m | |
| Co-Founder | 6.8yrs | US$1.43m | 1.31% $ 577.0k | |
| lead Independent Director | 3.7yrs | US$117.75k | 2.76% $ 1.2m | |
| Independent Director | 3.3yrs | US$82.75k | no data | |
| Member of Scientific Advisory Board | 5.3yrs | no data | no data | |
| Independent Director | 5.8yrs | US$94.25k | 0% $ 0 | |
| Member of Scientific Advisory Board | 1.1yrs | no data | no data | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 2.8yrs | US$83.25k | 0% $ 0 | |
| Independent Director | 5.8yrs | US$89.25k | 0.024% $ 10.6k | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Independent Director | 5.8yrs | US$80.25k | 0% $ 0 |
5.5yrs
Average Tenure
51yo
Average Age
Experienced Board: RAIN's board of directors are considered experienced (5.5 years average tenure).